Resolution of racemic 3-(naphthalen-1-yloxy)-2-aminopropane derivatives—key building blocks for central nervous system drug candidates—has been systematically re-evaluated using (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid as a chiral salt-forming agent under kinetic resolution conditions in a micro-packed-bed reactor. The diastereomeric salt pair exhibits a solubility differential exceeding 12 mg·mL⁻¹ in methyl isobutyl ketone at 278 K, enabling a single-pass enantiomeric enrichment to 99.2% ee at 40% conversion when the chiral acid is charged at 0.48 molar equivalents relative to racemate feed. The process replaces mandelic acid-based protocols that required six recrystallization cycles. Downstream liberation of the free amine is accomplished by partitioning the purified salt between 2.0 M aqueous sodium hydroxide and tert-butyl methyl ether, followed by vacuum distillation (0.1 mbar, 110–115 °C jacket temperature) on a wiped-film evaporator (L/D ratio 4.5:1, rotor speed 380 rpm). The resolved (R)-amine subsequently undergoes reductive amination with trityl-protected imidazole-4-carboxaldehyde to yield chiral N-substituted intermediates that are elaborated into potent histamine H₃ receptor inverse agonists, a terminal product class manufactured under ICH Q7 and ICH Q11 guidelines with residual solvent levels monitored per USP <467>. In pilot campaigns exceeding 120 kg isolation scale, batch-to-batch diastereomeric purity control is achieved via inline FTIR monitoring of the C=O stretching band at 1,715 cm⁻¹ and the carboxylate peak at 1,590 cm⁻¹, ensuring the Δ absorbance ratio does not drift beyond ±0.05 from the qualified reference signature.
Can (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid outperform D-(−)-tartaric acid in the classical resolution of 3-aminoquinuclidine dihydrochloride at multi-ton scale?
Direct comparative campaigns run in a 1,500 L glass-lined split-coil crystallizer evaluated the chiral pyrrolidine acid against the incumbent D-(−)-tartaric acid for the resolution of 3-aminoquinuclidine, a bicyclic amine supplied to inhalation anticholinergic and 5-HT₃ antagonist programs. With the pyrrolidine acid charged at 0.52 equivalents to 3-aminoquinuclidine free base (pre-released from its dihydrochloride salt by sodium methoxide treatment in anhydrous ethanol), the (R)-enantiomer crystallizes as a monohydrate salt from 92:8 v/v isopropanol/water in 94% yield within the first crop, exhibiting an enrichment factor 1.9× higher than the tartrate system. The salt formation is performed under a nitrogen blanket with controlled addition of the chiral acid as a 35 wt% solution in ethanol at 55 °C, followed by linear cooling to 5 °C at 0.15 K·min⁻¹ using a Huber Unistat 550 W circulation thermostat. The resulting crystalline salt is filtered on a Hastelloy centrifuge and washed with chilled isopropanol to reduce the 2,3-dimethoxyphenyl impurity carry-over to below 0.08% GC area. Industrial qualification under ICH Q3D demonstrates that palladium and iron levels from the preceding catalytic hydrogenation step are retained in the mother liquor, with the isolated salt containing less than 0.5 μg·g⁻¹ each. The terminal active pharmaceutical ingredients manufactured from this intermediate—tiotropium bromide and related quinuclidinyl benzilate M₃ receptor antagonists—must meet powdered-inhaler aerodynamic particle size distribution criteria per Ph. Eur. 2.9.18, a constraint that pushes up-polymerization impurity specifications for the chiral intermediate below 0.10%. This is verified via ultra-high performance liquid chromatography coupled to charged aerosol detection, a method that reveals the pyrrolidine acid resolution generates an impurity profile at least 35% less complex than the tartrate analogue when extracted ion chromatograms are overlaid.
When coupled with 2,3-dimethoxyphenylacetic acid in a sequential Sonogashira–Michael cascade for CNS-penetrant CRF₁ receptor antagonists
Integration of the chiral pyrrolidine acid into an advanced intermediate for corticotropin-releasing factor type 1 receptor antagonists begins with activation of the carboxylic acid to the corresponding Weinreb amide using N,O-dimethylhydroxylamine hydrochloride and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in the presence of catalytic 1-hydroxybenzotriazole at 0–5 °C in dichloromethane. The amide is then elaborated via Kumada coupling with 3-methoxyphenylmagnesium bromide, quenched, and the ketone intermediate immediately taken into a diastereoselective reduction with sodium borohydride–zinc chloride complex in tetrahydrofuran/diethylene glycol dimethyl ether (2:1 v/v) at -15 °C. This sequence furnishes a benzylic alcohol with an epimeric ratio of 97.5:2.5, which is subsequently converted to the mesylate and displaced with 2,6-dichloroisonicotinonitrile under phase-transfer conditions (tetrabutylammonium hydrogen sulfate, toluene/50% aqueous KOH). The resulting nitrile is hydrolyzed to a primary amide under microwave-assisted conditions at 130 °C for 25 min in a vessel achieving a dielectric heating ramp of 4.2 K·s⁻¹. Downstream processing on a pilot-scale production line involves neutral alumina filtration to remove boron-derived residues and isolation of the final crystalline CRF₁ antagonist precursor as a hydrochloride salt from acetone. During technology transfer to CMOs, the recommended charge of (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid is maintained at 1.03±0.02 molar equivalents relative to the Weinreb amide substrate to compensate for a 2-4% self-condensation loss observed in reactors with high surface-area-to-volume ratios. Finished CRF₁ antagonists produced via this route are classified as small-molecule schedule I psychotropic intermediates within the EU, requiring full REACH registration (Annex VII– VIII) and compliance with Directive 2001/83/EC Annex I for active substance master files. In-process control testing against impurity F (a de-dimethoxy congener arising from ether cleavage when local pH exceeds 12.5) is performed via HPLC with a 1.7 μm sub‑2‑micron C18 column, with a quantification limit set at 0.03%.
Ultra-low catalyst loadings of zero-valent palladium species supported on layered double hydroxide matrices are achieved when (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid serves as a chiral modifier of the metal surface atop a continuous stirred-tank reactor train dedicated to asymmetric allylic amination of Morita–Baylis–Hillman acetates with indoline nucleophiles. The chiral acid is pre-adsorbed onto a Pd/Al₂O₃ catalyst bed from a 0.08 wt% methanolic solution (pH 8.5, adjusted with triethylamine) for 18 h at 25 °C prior to the introduction of the substrate stream. At a modifier surface coverage of 0.02 monolayer equivalents, the enantioselectivity for the (S)-β-amino ester product reaches 88% ee at full conversion, a value that collapses to 12% ee when the phenyl ring of the modifier is unsubstituted or when a 2,4-dimethoxy regioisomer is deployed. The chemical manufacture of the immobilized chiral modifier itself is governed by ICH Q7 paragraph 12.1, with a certificate of analysis that includes a 99.0% minimum chiral purity specification and particle size distribution d₉₀ < 35 μm to ensure homogeneous packing of the catalyst basket. On a production line operating a 4.5 L CSTR cascade with a residence time combination of 8 + 12 + 15 min, catalyst deactivation follows a first-order rate constant of 0.02 h⁻¹, necessitating a mid-campaign regeneration protocol with acetylacetone in isopropanol. The terminal products—indoline-substituted α-amino acid derivatives—are registered as late-stage intermediates for integrase strand transfer inhibitors, a class of antiretroviral APIs that must adhere to the residual-metal specifications of E6 guideline for elemental impurities (Guideline for Elemental Impurities, ICH Q3D), often requiring an additional mercaptopropyl-functionalized silica scavenger column before crystallization.
Electrophilic amidation in continuous flow: (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid as a masked amine source for thermolabile orexin receptor inhibitors
A Curtius rearrangement-based telescoped process exploits the carboxylic acid moiety to install a primary amine handle required for the construction of dual orexin OX₁/OX₂ receptor antagonists used in phase III insomnia trials. The free acid is first activated to the acyl azide with diphenylphosphoryl azide and triethylamine in acetonitrile at -5 °C in a continuous stirred reactor (volume 18 mL), then immediately delivered to a heated residence coil (1.6 mm ID, 15 m length) maintained at 82 °C where the Curtius rearrangement proceeds to form the isocyanate intermediate. Trapping with tert-butanol generates the Boc-protected amine, which is telescoped directly into a Buchwald–Hartwig amination with 2-bromo-5-cyanopyridine without isolation. The chiral acid charge is fixed at 0.98 equivalents relative to diphenylphosphoryl azide to avoid accumulation of hydrazoic acid in the headspace, a safety boundary validated by adiabatic calorimetry (ARSST, Fauske Associates) showing an onset temperature of runaway decomposition of 138 °C for the neat acyl azide. Commissioning runs on a Corning Advanced-Flow G1 reactor achieve a throughput of 125 g·h⁻¹ with a total residence time of 23 min across all three modules, demonstrating steady-state impurity profiles with ≤ 0.15% of the dimeric urea by-product. The regulatory framework for such advanced intermediates falls under ICH M7 for mutagenic impurity control, and the diazide reagent’s by-product profile is quantitatively assessed by LC-MS/MS using MRM transitions for the N-oxide and hydrazide species at reporting thresholds of 5 ppm. The final orexin antagonist tablets are manufactured under 21 CFR Part 211 and must pass dissolution testing per USP <711> at pH 4.5 acetate buffer, a property influenced by the polymorphic form of the API traceable to the chiral amine crystallinity controlled during the salt formation step.
| Parameter | (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid | (R)-1-phenylethylamine (incumbent) | Test method |
|---|---|---|---|
| Diastereomeric excess after one crystallization | ≥99.2% de | 87–92% de | Supercritical fluid chromatography, Chiralpak IG-3, 150×4.6 mm |
| Minimum recyclable yield of auxiliary | 91% | 78% | Mass balance after acid extraction and sublimation |
| Residual auxiliary in final amine (ppm) | ≤45 | ≥210 | GC headspace, Agilent 7697A, DB-624 |
| Process safety: thermal onset (°C) | 212 | 159 | Differential scanning calorimetry, 10 K·min⁻¹ |
| Compliance standard | ICH Q3C (Class 2 residuals), REACH SVHC negative | ICH Q3C (methanol control) | — |
Suppression of out-of-specification α-glycosidic bond cleavage during the convergent assembly of a macrocyclic tyrosinase inhibitor relies on the use of (3R,4S)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid as a temporary chiral directing group on a 3,4-dihydroxyphenylalanine residue. The acid is coupled to the dopamine moiety via a mixed anhydride generated with isobutyl chloroformate and N-methylmorpholine in THF at -20 °C, achieving 97% conversion in 15 min. The resulting amide undergoes regioselective ortho-lithiation at the dimethoxyphenyl ring using 3.2 equivalents of n‑butyllithium/TMEDA complex in cumene at -40 °C, enabling introduction of a formyl group via DMF quench within a narrow temperature window of -35 to -45 °C. Deviation by as little as ±7 °C from the optimal lithiation temperature triggers irreversible demethoxylation and generates a deoxy impurity that co-elutes with the target compound in preparative reverse-phase chromatography. Scale-up to 80 kg input of the protected amino acid requires an automated cryogenic reactor cascade (Max Planck Institute-type jacketed vessel design) with a heat transfer coefficient maintained above 180 W·m⁻²·K⁻¹ via a recirculated Syltherm XLT loop. The directing group is removed chemoselectively by hydrogenolysis over 5% Pd/C at atmospheric pressure, a step whose endpoint is confirmed by the disappearance of the 1,510 cm⁻¹ aromatic C=C band in inline ReactIR analysis. Finished tyrosinase inhibitor formulations (topical dermatological creams) are produced under ISO 22716:2007 cosmetic GMP guidelines, and trace levels of the pyrrolidine cleavage fragment are monitored by UPLC-QTOF to meet a dermal sensitization threshold calculated per SCCS/1602/18.
